Eight months after Briumvi’s initial green light in the U.S., TG Therapeutics is preparing to debut its multiple sclerosis antibody on the world stage. In a deal unveiled Tuesday, European specialty ...
TG Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.28, expectations were $-0.37. Operator: Greetings, and welcome to the TG Therapeutics First Quarter 2023 Earnings Call. At this ...
Approved in February of 2021, TG Therapeutics’ first-in-class drug Ukoniq was billed as a potentially safer treatment for lymphoma patients. But 16 months later, the FDA has rescinded its approval of ...
Only three people in the world got to drive the new Cybertruck before Tesla's Texas handover event: TG's Jack Rix, YouTube tech expert Marques Brownlee and US car journalist Jason Cammisa. We gather ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback